Searched for
GLAXOSMITHKLINE PHARMA INDIA
More macro headwinds on the cards? Tackle them with core principles: 6 pharma stocks with upside potential of up to 28%There was a time when the Indian pharma story in the US was almost entirely about inspection risk. The US FDA would inspect a plant, a warn...- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 22%As the market grappled with confusion over the Strait of Hormuz, there was more trouble for the bulls. After a few days of respite, another...
- Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...
- GSK's Calpol a well-known trademark: High CourtThe Delhi High Court has recognized GlaxoSmithKline Pharmaceuticals' pain and fever medicine, Calpol, as a well-known trademark. This desig...
- Bombay HC backs GSK in Paxil trademark row against Shreya Life SciencesThe Indian subsidiary of the UK-based GSK PLC had urged the court to cancel the mark used by the local company in pharmaceutical and medici...
- I-Sec upgrades GlaxoSmithKline Pharma to Add, lowers target price to Rs 2,250ICICI Securities has raised its rating on GlaxoSmithKline Pharmaceuticals to Add from Hold with a new target price of Rs 2250. GSK Pharma's...
- Will PLI help Indian pharma gain market share at cost of MNCs?Indian pharmaceutical companies are becoming more aggressive and increasing their market share and capex. Companies such as Divis, Dr Reddy...
- Focus on 20 key brands to drive growth: GlaxoSmithKline pharmaceuticalsAs part of its growth plans the company is also planning to aggressively expand its field force.
- Ambuja Cements, Aurobindo Pharma, Bosch to move out of Nifty from April 2Ambuja Cements, Aurobindo Pharma, Bosch to move out of Nifty from April 2.
- GSK Pharma to transfer cancer drug portfolio to Novartis armGlaxoSmithKline Pharmaceuticals board approved transfer of its cancer drugs portfolio to an arm of Novartis in India in return for acquirin...
- Novartis shares up nearly 2% at closeShares of Novartis India ended nearly 2% higher after fair trade regulator CCI approved a multi-billion dollar deal between GlaxoSmithKline...
- Govt clears GlaxoSmithKline's Rs 6,400 crore FDI proposalThe Cabinet Committee on Economic Affairs has approved the proposal of GlaxoSmithKline Pte Limited, Singapore for acquisition of 24.33 per ...
- Nine foreign investment proposals worth Rs 798.73 crore approvedThe Ministry said it approved the nine proposals following recommendations of the Foreign Investment Promotion Board (FIPB).
- FIPB clears GlaxoSmithKline's Rs 6,400 cr FDI proposalFIPB today cleared Rs 6,400 crore FDI proposal of GlaxoSmithKline to acquire additional 24.33 per cent stake in its India arm.
- FIPB to decide on GlaxoSmithKline, other pharma FDI proposalsFIPB will take up tomorrow GlaxoSmithKline's Rs 6,400 crore FDI plan, the largest foreign investment proposal in the pharma sector this fis...
- GSK's open offer for buying stake in Indian arm from February 7-21GlaxoSmithKline Plc's Rs 6,389.02 crore open offer to pick up 24.33 per cent stake in its Indian arm GlaxoSmithKline Pharma will start from...
- Parent offer talk spurs GSK PharmaIt may be the season of open offers by MNCs. GlaxoSmithKline Consumer started it earlier this year, followed by Unilever and, the latest, M...
- Apollo Hospitals, GSK Consumer hit 52-week highs on inclusion in MSCI India IndexInclusions in MSCI small-cap index includes stocks like Alembic Pharma, CARE, eClerx, Godrej Properties and JK Cement.
- GSK gets Sebi nod for GlaxoSmithKline Consumer open offerThe offer is scheduled to open from Jan 17, according to the announcement made by HSBC on behalf of GSK and is expected to close on January...
- GlaxoSmithKline Pharma to launch more vaccines in IndiaDrug major GlaxoSmithKline Pharmaceuticals on MOnday said it would be launching more vaccines in the Indian market.
Load More
